JPRN-UMIN000001984
Completed
未知
Evaluation of Ranibizumab for diabetes macular edema - Evaluation of Ranibizumab for diabetes macular edema
Yamagata University faculty of Medecine,department of ophthalmology0 sites10 target enrollmentOctober 1, 2010
Conditionsdiabetes macular edema
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- diabetes macular edema
- Sponsor
- Yamagata University faculty of Medecine,department of ophthalmology
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Tha patients who has history of myocardial infarction and brain infarction.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Lucentis (Ranibizumab) in patients with visual impairment due to diabetic macular oedema.EUCTR2010-022616-39-GBovartis Pharmaceuticals UK Ltd
Completed
Phase 2
Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 StudyDiabetic Macular EdemaNCT01077401Johns Hopkins University152
Completed
Phase 2
The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) StudyDiabetic Macular EdemaNCT00407381Johns Hopkins University126
Completed
Not Applicable
Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)Diabetic Macular EdemaNCT05815212Novartis Pharmaceuticals87
Withdrawn
Phase 2
Ranibizumab as a Rescue Therapy for Diabetic Macular EdemaDiabetic Macular EdemaNCT01253694New England Retina Associates